الفهرس 
HCV InfectionOnly 14 pages are availabe for public view
 |  | from | 201 |  |  |
| | | from | 201 | | |
Abstract
Abstract
Introduction: Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells. The acute stage of the disease passes mostly without manifestations, but the chronic stage can cause hepatic fibrosis and cirrhosis, that has mostly occurred after several years. Some cirrhotic patients may develop liver failure, hepatocellular carcinoma (HCC) or fatal bleeding from esophageal or gastric varices.
Aims: The aim of this study is to compare between the clinical outcome of Simeprevir plus Sofosbuvir regimen and Daclatasvir plus Sofosbuvir regimen in the management of Treatment-naïve chronic Hepatitis C Egyptian patients with compensated cirrhosis and non-cirrhotic patients as regards to sustained virological response (SVR) at the end of treatment and 12 weeks after the end of treatment and the clinical data till the end of the treatment.
Patients and Methods: This study has been conducted at the Viral Hepatitis Unit – Ahmed Maher Teaching Hospital – National committee for the control of viral hepatitis (NCCVH) during the period from June 2015 to November 2016.
Results: 400 Egyptian treatment-naïve chronic hepatitis C patients were recruited in this study and were divided into 2 groups:
group I: 200 patients received fixed daily dose (400mg Sofosubvir +150mg Simeprevir) for 12 weeks.
group II: 200 patients received fixed daily dose (400mg Sofosubvir +60mg Daclatasvir) for 12 weeks.
Conclusion: Both (simeprevir plus sofosbuvir) and (daclatasvir plus sofosbuvir) oral regimens for treatment of chronic HCV infected patients with or without compensated cirrhosis are effective and well tolerated, with non-significant difference between them.
Recommendation: Both (simeprevir plus sofosbuvir) and (daclatasvir plus sofosbuvir) oral regimens for 12 weeks are good options in the treatment of chronic HCV infected patients with or without compensated cirrhosis. Careful monitoring of CBC, liver enzymes, serum bilirubin and serum creatinine during treatment.
Keywords: Simeprevir Plus, Sofosbuvir Regimen Daclatasvir Plus Sofosbuvir, Treatment of chronic Hepatitis C